PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
PHI publishes prospectus due to upcoming rights issue
PostNews
BioStock: Studio interview with Anders Månsson and Goran Dubravčić
Recently, PHI welcomed Anders Månsson as its new CEO. In a video interview, Månsson and Chairman of the Board Goran Dubravčić discuss the company’s future strategy and the ongoing rights issue.
PostNews: Press Release
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 2 December 2024
Today, 2 December 2024, an Extraordinary General Meeting was held in Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”). The adopted resolution is summarized below.
PostNews: Press Release
Altium SA places order to a value of EUR 460 K and PHI communicates sales outlook
PHI AB today announces that the Company’s global distributor Altium SA has placed an order of HoloMonitor® systems and add-ons to a total value of approximately EUR 460 K. The total expected order value from Altium for the full fiscal year of 2024/2025 is estimated to amount to approximately EUR 2 million.
PostNews: Interim Report
Interim Report 2 2024/25
Sales grew significantly in Q2 vs. the same period last year, but only moderately YTD vs. the same period last year. Discounting on demo kits for our new distributors reduced the gross margin. Overall costs remain stable. The absolute key to transforming the company, both short-term and long-term, is a significant increase in sales, which the agreement with Altium promises to deliver.
PostNews: Press Release
Early publication of Interim Report 2, 2024/2025
Phase Holographic Imaging PHI AB (publ) hereby announces that the Board of Directors has decided to bring forward the company’s report for Q2, 2024/2025 to November 28, 2024. This is because the company wishes to publish the report prior to the Extraordinary General Meeting planned for Dec 2.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
BioStock: PHI aims for US listing
BioStock has talked to PHI’s CEO, Patrik Eschricht, to learn more about what the dual listing on the US OTCQB market means for the company and its plans for the future.
BioStock: PHI grows its network of collaborations
BioStock caught up with PHI’s CEO Patrik Eschricht to ask about his outlook for the growing number of academic collaborations and sales partnerships.
BioStock: PHI “It’s the right moment to capitalize on regenerative medicine momentum.”
BioStock contacted CEO Patrik Eschricht for an update on the company’s progress and how PHI will capitalize on the current momentum.
BioStock: Shift to regenerative medicine increases growth prospects for PHI
BioStock talked to our CEO, Patrik Eschricht, for an operational overview and to learn about the current behind-the-scenes developments, as PHI has a growth trajectory that is on a notable upward trend, marked by its highest-ever sales performances in the last quarter.
